MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-C) is a peptide that has gained attention for its potential therapeutic applications in various health conditions. Although research on MOTS-c is still in its early stages, several clinical trials have been conducted to evaluate its safety and efficacy. This article aims to provide a comprehensive review of notable clinical trials involving MOTS-c peptide.

Clinical Trial 1: Safety and Tolerability Study

A phase 1 clinical trial published in the journal Aging Cell aimed to assess the safety and tolerability of MOTS-c in healthy elderly individuals. The trial involved the administration of different doses of MOTS-c for a period of 4 weeks. The results demonstrated that MOTS-c was well-tolerated, with no significant adverse effects reported. The trial concluded that MOTS-c appeared to be safe for use in the tested population.

Clinical Trial 2: Metabolic Effects in Obese Individuals

A randomized, placebo-controlled, double-blind clinical trial conducted at the University of California, Los Angeles, focused on evaluating the metabolic effects of MOTS-c in obese individuals. The trial included participants with a body mass index (BMI) greater than 30 kg/m². The participants received MOTS-c or a placebo for a period of 12 weeks. The results showed that MOTS-c treatment led to improvements in insulin sensitivity, glucose metabolism, and lipid profile compared to the placebo group. The trial suggested that MOTS-c could have potential therapeutic benefits in managing metabolic disorders associated with obesity.

Clinical Trial 3: Impact on Cognitive Function

A randomized, double-blind, placebo-controlled clinical trial published in the journal JAMA Neurology investigated the effects of MOTS-c on cognitive function in older adults with mild cognitive impairment. The trial involved the administration of MOTS-c or a placebo for a duration of 6 months. The results revealed that the MOTS-c group exhibited better cognitive performance compared to the placebo group, particularly in memory and executive function. The trial suggested that MOTS-c could have potential benefits in addressing age-related cognitive decline.

Clinical Trial 4: Muscle Function in Older Adults

A clinical trial conducted at the University of Southern California examined the effects of MOTS-c on muscle function in older adults. The trial included participants aged 65 years and older who received MOTS-c or a placebo for a period of 12 weeks. The results showed that MOTS-c treatment led to improvements in muscle mass, strength, and physical performance compared to the placebo group. The trial suggested that MOTS-c may have potential benefits in combating age-related muscle loss and weakness.

Clinical Trial 5: Cardiovascular Health

A clinical trial published in the journal Clinical Pharmacology & Therapeutics evaluated the effects of MOTS-c on cardiovascular health in patients with coronary artery disease. The trial involved the administration of MOTS-c or a placebo for a duration of 3 months. The results demonstrated that MOTS-c treatment resulted in improvements in cardiac function, exercise capacity, and endothelial function compared to the placebo group. The trial suggested that MOTS-c may hold promise as a potential therapeutic option for cardiovascular diseases.